Literature DB >> 19132288

Achyranthoside H methyl ester, a novel oleanolic acid saponin derivative from Achyranthes fauriei roots, induces apoptosis in human breast cancer MCF-7 and MDA-MB-453 cells via a caspase activation pathway.

Motonori Fukumura1, Hidehiro Ando, Yasuaki Hirai, Kazuo Toriizuka, Yoshiteru Ida, Yoshiyuki Kuchino.   

Abstract

Achyranthoside H methyl ester (AH-Me) is an oleanolic acid saponin derivative isolated from the roots of Achyranthes fauriei through diazomethane treatment. AH-Me exhibited significant cytotoxicity against human breast cancer MCF-7 and MDA-MB-453 cells, with respective ID(50) values of 4.0 and 6.5 muM: in the MTT assay. AH-Me is a unique saponin containing three methoxycarbonyl groups in the sugar moiety linked to the C-3 position of oleanolic acid. The demethylation of these methoxycarbonyl groups by alkaline hydrolysis caused a marked reduction of the cytotoxicity of AH-Me, suggesting that the methoxycarbonyl groups of AH-Me are key groups for the acquisition of cytotoxicity against human cancer cells. The staining of cancer cells with 4',6'-diamidino-2-phenylindole (DAPI) showed that the population of cells with altered nuclear morphology, for example chromatin condensation and fragmentation, increased markedly after AH-Me treatment. Exposure of MCF-7 and MDA-MB-453 cells to AH-Me resulted in a dose-dependent and time-dependent increase in the sub-G1 population, and in the cleavage of poly-ADP-ribose polymerase (PARP) followed by the formation of an 89 kD peptide. Pretreatment of the cells with the pan-caspase inhibitor z-VAD-fmk abolished the cleavage of PARP by AH-Me treatment and suppressed the antiproliferative effect of AH-Me on tumor cell growth. These results together led to the suggestion that AH-Me induces apoptosis via the caspase activation pathway in human breast cancer cells, and apoptosis is the major mode of the cytotoxic effect triggered by AH-Me.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132288     DOI: 10.1007/s11418-008-0311-7

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  24 in total

1.  Apoptosis in the absence of caspase 3.

Authors:  Y Liang; C Yan; N F Schor
Journal:  Oncogene       Date:  2001-10-04       Impact factor: 9.867

Review 2.  Role of HER2 gene overexpression in breast carcinoma.

Authors:  S Ménard; E Tagliabue; M Campiglio; S M Pupa
Journal:  J Cell Physiol       Date:  2000-02       Impact factor: 6.384

Review 3.  Role of erbB2 in breast cancer chemosensitivity.

Authors:  D Yu; M C Hung
Journal:  Bioessays       Date:  2000-07       Impact factor: 4.345

4.  Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7.

Authors:  M Germain; E B Affar; D D'Amours; V M Dixit; G S Salvesen; G G Poirier
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

Review 5.  Caspase function in programmed cell death.

Authors:  S Kumar
Journal:  Cell Death Differ       Date:  2006-11-03       Impact factor: 15.828

6.  Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK.

Authors:  Filippa Pettersson; Marie-Claude Couture; Nessrine Hanna; Wilson H Miller
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

7.  Mining of caspase-7 substrates using a degradomic approach.

Authors:  Mi Jang; Byoung Chul Park; Sunghyun Kang; Do Hee Lee; Sayeon Cho; Sang Chul Lee; Kwang-Hee Bae; Sung Goo Park
Journal:  Mol Cells       Date:  2008-07-03       Impact factor: 5.034

8.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Authors:  Chad J Creighton; Suleiman Massarweh; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Jiang Shou; Luca Malorni; Rachel Schiff
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 9.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Authors:  Aleix Prat; José Baselga
Journal:  Nat Clin Pract Oncol       Date:  2008-07-08

10.  Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.

Authors:  Abeer M Shaaban; Andrew R Green; Suchita Karthik; Yalda Alizadeh; Thomas A Hughes; Lynn Harkins; Ian O Ellis; John F Robertson; Emma C Paish; Philippa T K Saunders; Nigel P Groome; Valerie Speirs
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

View more
  4 in total

1.  Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.

Authors:  Nisha R Parikh; Animesh Mandal; Deepak Bhatia; Kodappully Sivaraman Siveen; Gautam Sethi; Anupam Bishayee
Journal:  Phytochem Rev       Date:  2014-12       Impact factor: 5.374

Review 2.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

3.  Tissue-based metabolite profiling and qualitative comparison of two species of Achyranthes roots by use of UHPLC-QTOF MS and laser micro-dissection.

Authors:  Yogini Jaiswal; Zhitao Liang; Alan Ho; Hubiao Chen; Leonard Williams; Zhongzhen Zhao
Journal:  J Pharm Anal       Date:  2017-06-16

Review 4.  Saponin constituents of Achyranthes root.

Authors:  Fumiyuki Kiuchi
Journal:  J Nat Med       Date:  2022-01-04       Impact factor: 2.343

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.